000			02320nam a2200481 i 4500
999			_c272754 _d272754
001			on1042073861
003			OCoLC
005			20180801080555.0
006			m o d f
007			cr bn||||a||||
008			180627s2018 dcu o f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1020-C (online)
086	0		_aY 4.J 89/1:115-27
088			_aSerial no. 115-27 (United States. Congress. House. Committee on the Judiciary)
099			_aY 4.J 89/1:115-27
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on the Judiciary. _bSubcommittee on Regulatory Reform, Commercial and Antitrust Law,
245	1	0	_aAntitrust concerns and the FDA approval process : _bhearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fifteenth Congress, first session, July 27, 2017.
246	3		_aAntitrust concerns and the Food and Drug Administration approval process
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_a1 online resource (iv, 51 pages)
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_a"Serial no. 115-27."
500			_aCRDP Program record.
588			_aDescription based on online resource; title from PDF title screens (govinfo web site, viewed on June 27, 2018).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on the Judiciary. Subcommittee on Regulatory Reform, Commercial and Antitrust Law. _tAntitrust concerns and the FDA approval process _w(OCoLC)1042073889
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo93483
050		4	_aKF27 _b.J874 2017h
610	1	0	_aUnited States. _bFood and Drug Administration _xRules and practice.
650		0	_aDrugs _zUnited States _xTesting.
650		0	_aDrug approval _zUnited States.
650		0	_aDrugs _xSafety regulations _zUnited States.
650		0	_aMedical instruments and apparatus _xSafety regulations _zUnited States.
650		0	_aGeneric drugs _zUnited States.
650		0	_aCompetition _zUnited States.
650		0	_aAntitrust law _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8